Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.
Wennmann M, Ming W, Bauer F, Chmelik J, Klein A, Uhlenbrock C, Grözinger M, Kahl KC, Nonnenmacher T, Debic M, Hielscher T, Thierjung H, Rotkopf LT, Stanczyk N, Sauer S, Jauch A, Götz M, Kurz FT, Schlamp K, Horger M, Afat S, Besemer B, Hoffmann M, Hoffend J, Kraemer D, Graeven U, Ringelstein A, Bonekamp D, Kleesiek J, Floca RO, Hillengass J, Mai EK, Weinhold N, Weber TF, Goldschmidt H, Schlemmer HP, Maier-Hein K, Delorme S, Neher P. Wennmann M, et al. Among authors: mai ek. Invest Radiol. 2023 Oct 1;58(10):754-765. doi: 10.1097/RLI.0000000000000986. Epub 2023 May 22. Invest Radiol. 2023. PMID: 37222527
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Mai EK, et al. Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19. Leukemia. 2015. PMID: 25787915 Clinical Trial.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Merz M, et al. Among authors: mai ek. Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3. Haematologica. 2015. PMID: 25840597 Free PMC article. Clinical Trial.
Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K, Schönland S, Hegenbart U, Wallenwein K, Braun U, Mai EK, Hillengass J, Goldschmidt H, Jauch A, Ho AD, Raab M, Hundemer M. Lisenko K, et al. Among authors: mai ek. Cytometry B Clin Cytom. 2017 Mar;92(2):145-152. doi: 10.1002/cyto.b.21351. Epub 2016 Feb 3. Cytometry B Clin Cytom. 2017. PMID: 26666746 Free article.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Baertsch MA, et al. Among authors: mai ek. BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2. BMC Cancer. 2016. PMID: 27114074 Free PMC article. Clinical Trial.
57 results